Form Type: 4

SEC EDGAR Link
Accession Number:0000899243-21-036769
Date:2021-09-17
Issuer: BIOMEA FUSION, INC. (BMEA)
Original Submission Date:

Reporting Person:

A2A PHARMACEUTICALS, INC.
C/O BIOMEA FUSION, INC.
726 MAIN STREET REDWOOD CITY, CA 94063

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-09-17 P 34,658 a $10.96 4,400,000 f2 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 the price reported is a weighted average price. the shares were sold in multiple transactions at per share prices ranging from $10.89 to $11.04. the reporting person undertakes to provide upon request to the sec staff, the issuer, or any stockholder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
f2 these shares are held directly by a2a pharmaceuticals inc. sotirios stergiopoulos is a member of the issuer's board of directors and is an affiliate of the reporting person.
WhaleWisdom Logo

Elevate your investments